24 results
Thumbnail

- D3.196 - Efficacy of sublingual immunotherapy in children with allergic rhinitis

Thumbnail

D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study

Thumbnail

D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study

Thumbnail

D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives

Thumbnail

D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus

Thumbnail

D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy

Thumbnail

D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania

Thumbnail

D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts

Thumbnail

D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment

Thumbnail

D3.205 - Online Education Increases Clinician Knowledge and Confidence in Utilizing Allergen Immunotherapy for Respiratory Allergic Disease

Thumbnail

D2.167 - Effect of Metformin on allergen specific immunotherapy

Thumbnail

D2.169 - Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children

Thumbnail

D2.174 - Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT

Thumbnail

D2.179 - Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study

Thumbnail

D2.168 - Systemic reactions to subcutaneous immunotherapy in children

Thumbnail

D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season

Thumbnail

D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment

Thumbnail

D2.172 - Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions

Thumbnail

D2.173 - Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis

Thumbnail

D2.175 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS